
Neeraj Agarwal/X
Jun 6, 2025, 00:52
Neeraj Agarwal: Andrew Armstrong Shares 5-Year Survival Data from Arches Trial in mHSPC Prostate Cancer
Neeraj Agarwal, Postdoctoral fellow at City of Hope, shared a post on X:
“Congrats Andrew Armstrong for the 5-yr follow-up OS results from ph3 Arches trial in mHSPC prostate cancer with enzalutamide. 66% probability of survival at 5 yrs & 30% reduction of risk of death with enzalutamide.”
Read OncoDaily’s Special Articles about ASCO 2025:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 5, 2025, 15:47
Jun 5, 2025, 15:44
Jun 5, 2025, 15:07